Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
09 janv. 2025 16h00 HE
|
Aptose Biosciences, Inc.
Aptose Announces First AML Patients Dosed with
Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
12 déc. 2024 10h15 HE
|
Aptose Biosciences, Inc.
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
03 déc. 2024 07h30 HE
|
Aptose Biosciences, Inc.
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
20 nov. 2024 07h30 HE
|
Aptose Biosciences, Inc.
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
Aptose Reports Results for the Third Quarter 2024
08 nov. 2024 16h01 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
09 déc. 2023 18h30 HE
|
Aptose Biosciences, Inc.
ASH Oral Presentation: Complete Response Data from the Ongoing APTIVATE Phase 1/2 Study of Tuspetinib (TUS) in R/R AML Patients
Aptose Reports Results for the Third Quarter 2023
09 nov. 2023 16h00 HE
|
Aptose Biosciences, Inc.
Aptose Reports Results for the Third Quarter 2023
• TUS/VEN Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
02 nov. 2023 09h00 HE
|
Aptose Biosciences, Inc.
Dr. Naval Daver from MD Anderson Cancer Center will present data from Aptose’s AML Drug Candidate Tuspetinib in an Oral Presentation at ASH 2023
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
30 oct. 2023 09h15 HE
|
Aptose Biosciences, Inc.
Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
23 oct. 2023 07h30 HE
|
Aptose Biosciences, Inc.
Aptose to Hold Clinical Update Webcast and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th